Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

Front Immunol. 2021 Nov 23:12:800609. doi: 10.3389/fimmu.2021.800609. eCollection 2021.

Authors

Si-Hang Wang¹, Ya-Gang Zuo¹

Affiliation

¹ Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

No abstract available

Keywords: IL-13; IL-4; bullous pemphigoid; dupilumab; treatment.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Pemphigoid, Bullous* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
dupilumab